These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 26517962)

  • 1. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
    Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
    Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate-modified lipid-polymer hybrid nanoparticles for targeted paclitaxel delivery.
    Zhang L; Zhu D; Dong X; Sun H; Song C; Wang C; Kong D
    Int J Nanomedicine; 2015; 10():2101-14. PubMed ID: 25844039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
    Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
    Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib-Loaded Poly(ε-Caprolactone) Nanocapsules Improve In Vitro Cytotoxicity and Anticlonogenic Effects on Human A549 Lung Cancer Cells.
    Bruinsmann FA; Buss JH; Souto GD; Schultze E; de Cristo Soares Alves A; Seixas FK; Collares TV; Pohlmann AR; Guterres SS
    AAPS PharmSciTech; 2020 Aug; 21(6):229. PubMed ID: 32778976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
    Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
    Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced anticancer activity in vitro and in vivo of luteolin incorporated into long-circulating micelles based on DSPE-PEG2000 and TPGS.
    Yan H; Wei P; Song J; Jia X; Zhang Z
    J Pharm Pharmacol; 2016 Oct; 68(10):1290-8. PubMed ID: 27465923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysozyme-loaded lipid-polymer hybrid nanoparticles: preparation, characterization and colloidal stability evaluation.
    Devrim B; Kara A; Vural İ; Bozkır A
    Drug Dev Ind Pharm; 2016 Nov; 42(11):1865-76. PubMed ID: 27091346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and In Vitro Evaluation of Crizotinib-Loaded Lipid-Polymer Hybrid Nanoparticles Using Box-Behnken Design in Non-small Cell Lung Cancer.
    Korucu Aktas P; Baysal I; Yabanoglu-Ciftci S; Arica B
    AAPS PharmSciTech; 2023 Sep; 24(7):178. PubMed ID: 37658977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation.
    Zhou X; Tao H; Shi KH
    Drug Des Devel Ther; 2018; 12():1-8. PubMed ID: 29296076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central composite designed formulation, characterization and in vitro cytotoxic effect of erlotinib loaded chitosan nanoparticulate system.
    Pandey P; Chellappan DK; Tambuwala MM; Bakshi HA; Dua K; Dureja H
    Int J Biol Macromol; 2019 Dec; 141():596-610. PubMed ID: 31494160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
    He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
    Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
    Shaji J; Menon I
    Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and evaluation of carboplatin-loaded PCL nanoparticles for intranasal delivery.
    Alex AT; Joseph A; Shavi G; Rao JV; Udupa N
    Drug Deliv; 2016 Sep; 23(7):2144-2153. PubMed ID: 25544603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
    Pang J; Xing H; Sun Y; Feng S; Wang S
    Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer.
    Wang S; Gou J; Wang Y; Tan X; Zhao L; Jin X; Tang X
    Int J Nanomedicine; 2021; 16():2357-2372. PubMed ID: 33790554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer.
    Bakhtiary Z; Barar J; Aghanejad A; Saei AA; Nemati E; Ezzati Nazhad Dolatabadi J; Omidi Y
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1244-1253. PubMed ID: 28323493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment.
    Kulkarni NS; Parvathaneni V; Shukla SK; Barasa L; Perron JC; Yoganathan S; Muth A; Gupta V
    Eur J Pharm Sci; 2019 May; 133():145-159. PubMed ID: 30946965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.